Historical Valuation
SINOPHARM (01099) is now in the Fair zone, suggesting that its current forward PE ratio of 6.98 is considered Fairly compared with the five-year average of 6.44. The fair price of SINOPHARM (01099) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：20.30
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SINOPHARM (01099) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of 0.79 , the current P/B ratio is approximately -14.22% higher. Relative to its 5-year average P/B ratio of 0.81, the current P/B ratio is about -16.26% higher. SINOPHARM (01099) has a Forward Free Cash Flow (FCF) yield of approximately 34.31%. Compared to its 3-year average FCF yield of 25.36%, the current FCF yield is approximately 35.27% lower. Relative to its 5-year average FCF yield of 21.98% , the current FCF yield is about 56.07% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 01099 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01099 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 01099 currently overvalued or undervalued?
SINOPHARM (01099) is now in the Fair zone, suggesting that its current forward PE ratio of 6.98 is considered Fairly compared with the five-year average of 6.44. The fair price of SINOPHARM (01099) is between to according to relative valuation methord.
What is SINOPHARM (01099) fair value?
01099's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SINOPHARM (01099) is between to according to relative valuation methord.
How does 01099's valuation metrics compare to the industry average?
The average P/S ratio for 01099's competitors is , providing a benchmark for relative valuation. SINOPHARM Corp (01099) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SINOPHARM (01099) as of Jan 15 2026?
As of Jan 15 2026, SINOPHARM (01099) has a P/B ratio of 0.67. This indicates that the market values 01099 at 0.67 times its book value.
What is the current FCF Yield for SINOPHARM (01099) as of Jan 15 2026?
As of Jan 15 2026, SINOPHARM (01099) has a FCF Yield of 34.31%. This means that for every dollar of SINOPHARM’s market capitalization, the company generates 34.31 cents in free cash flow.
What is the current Forward P/E ratio for SINOPHARM (01099) as of Jan 15 2026?
As of Jan 15 2026, SINOPHARM (01099) has a Forward P/E ratio of 6.98. This means the market is willing to pay $6.98 for every dollar of SINOPHARM’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SINOPHARM (01099) as of Jan 15 2026?
As of Jan 15 2026, SINOPHARM (01099) has a Forward P/S ratio of 0.09. This means the market is valuing 01099 at $0.09 for every dollar of expected revenue over the next 12 months.